Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT8R1L
|
|||
| Drug Name |
DS-7300
|
|||
| Synonyms |
O-(3,5-dichlorophenyl)hydroxylamine; 99907-90-1; 3,5-Dichlorophenoxyamine; Hydroxylamine, O-(3,5-dichlorophenyl)-; SCHEMBL4210449; DTXSID00471352; MFCD09029771; ZINC21987339; AKOS006290319; AK141702
Click to Show/Hide
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1/2 | [1] | |
| Company |
Daiichi Sankyo
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B7 homolog 3 (CD276) | Target Info | Inhibitor | [2] |
| DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04145622) Study of DS-7300a in Participants With Advanced Solid Malignant Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Daiichi Sankyo. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.